| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.024 | 0.6 |
| mRNA | pac-1 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.031 | 0.6 |
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | skepinone-L | CTRPv2 | pan-cancer | AAC | 0.029 | 0.6 |
| mRNA | selumetinib:piperlongumine (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | -0.043 | 0.6 |